CSSi, a provider of patient recruitment solutions for the clinical research industry, recently announced the formation of the company's Medical and Clinical Advisory Board (MCAB) and the appointment of Ronald M. Bukowski, M.D., as its chairman.
The MCAB, with Bukowski's leadership, will help provide insight across a variety of therapeutic areas and set strategic goals for the advancement and development of CSSi's work within the clinical research industry to shorten the timelines of getting new drugs to market. Additionally, the MCAB will strive to identify best practices based on evidence and clinical guidelines to achieve optimum outcomes of research trials.
Bukowski is an emeritus staff at the Taussig Cancer Center and the Cleveland Clinic Foundation. He recently was professor of Medicine, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University and the deputy director of the Cleveland Clinic Taussig Cancer Center. He was the director of the Experimental Therapeutics Program at the Cleveland Clinic Cancer Center, and held the James Zito Chair in Cancer Research from 2001 to 2008. Bukowski is a fellow of the American College of Physicians and a member of numerous professional societies, including the American Society of Clinical Oncology and the American Association of Cancer Research.
He is a lifelong researcher with interests in new drug development and investigation, as well as biologic response modifiers and the biology of renal cell carcinoma. Currently, Bukowski is the chairman of the medical committee of the Kidney Cancer Association and chairman of its board of directors.
Additional physicians will be added in the near future, allowing for expansion of global regulatory specialties and therapeutic diversity which will reflect the international leadership position of CSSi in the patient recruitment industry.